Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5294238 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL5306836 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL30569522 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL10717990 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL1249217 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL8752673 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL4104862 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL2905602 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| Dodine SCHEMBL21643 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 | |
| SCHEMBL93899 | 1.00 | MEN1 (0.55) | MEN1CYP1A2KMT2ASMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116370039-A | Accurate ablation system of nanoparticle microblade mediated tumor | 南方医科大学 | 2023-07-04 | — | — | CN | claimed |
| CN-101538047-B | Method for preparing long-chain alkylguanidine-modified attapulgite | Huaiyin Normal University | 2010-11-17 | — | — | CN | claimed |
| CN-101538047-A | Method for preparing long-chain alkylguanidine-modified attapulgite | Huaiyin Normal University | 2009-09-23 | — | — | CN | claimed |
| US-4487826-A | EXCELLENT SHELF LIFE AND HEAT SENSITIVITY | TOPPAN PRINTING CO., LTD. (JP) | 1984-12-11 | — | — | US | claimed |
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR INC. (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2023250347-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM, AND FOULING FROM WATER SYSTEMS AND SURFACES | AEQUOR, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-116370039-A | Accurate ablation system of nanoparticle microblade mediated tumor | 南方医科大学 | 2023-07-04 | — | — | CN | disclosed |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2021003419-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-107848963-B | Acid-resistant alkali-producing agent and/or radical-producing agent, and curable resin composition containing same | 富士胶片和光纯药株式会社 | 2020-11-03 | — | — | CN | disclosed |
| WO-2018041377-A1 | CAPPED CYCLODEXTRIN-HYDROPHOBIC MOIETY CONJUGATE, CYCLODEXTRIN SUPRAMOLECULAR POLYMER, AND CYCLODEXTRIN-siRNA COMPLEX AND METHOD OF SYNTHESIS THEREOF | UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (FR) | 2018-03-08 | — | — | WO | disclosed |
| US-9316648-B2 | Urea-based synthetic urine and method of manufacturing same | SPECTRUM LABORATORIES, LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140329327-A1 | UREA-BASED SYNTHETIC URINE AND METHOD OF MANUFACTURING SAME | SPECTRUM LABORATORIES, LLC | 2014-11-06 | — | — | US | disclosed |
| CN-101538047-B | Method for preparing long-chain alkylguanidine-modified attapulgite | Huaiyin Normal University | 2010-11-17 | — | — | CN | disclosed |
| CN-101538047-A | Method for preparing long-chain alkylguanidine-modified attapulgite | Huaiyin Normal University | 2009-09-23 | — | — | CN | disclosed |
| US-7192776-B2 | Synthetic urine and method of manufacturing same | SPECTRUM LABORATORIES, LLC | 2007-03-20 | — | — | US | disclosed |
| US-20050164395-A1 | Synthetic urine and method of manufacturing same | SPECTRUM LABORATORIES, LLC | 2005-07-28 | — | — | US | disclosed |
| EP-0084890-B1 | DIAZOTYPE HEAT DEVELOPMENT RECORDING MEDIUM | Toppan Printing Co., Ltd. (JP) | 1986-05-21 | — | — | EP | disclosed |
| US-4487826-A | EXCELLENT SHELF LIFE AND HEAT SENSITIVITY | TOPPAN PRINTING CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0084890-A1 | Diazotype heat development recording medium | Toppan Printing Co., Ltd. (JP) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | GRHPR, HAO2, CBR1 | MEN1 4689/4885CYP1A2 1252/4885KMT2A 4120/4885 |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | PFAS, ERG28, DDT | MEN1 1641/4885CYP1A2 1662/4885KMT2A 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.